Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome
A Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome: A Randomized, Double-blind, Placebo-controlled Clinical Trial
Sponsor: American Diabetes Association
A PHASE2 clinical study on HIV Lipodystrophy, this trial is completed. The trial is conducted by American Diabetes Association and has accumulated 9 data snapshots since 2006. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
May 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — May 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Aug 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- American Diabetes Association
- Beth Israel Deaconess Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .